Welcome to our dedicated page for Vicapsys Life Sc news (Ticker: VICP), a resource for investors and traders seeking the latest updates and insights on Vicapsys Life Sc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vicapsys Life Sc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vicapsys Life Sc's position in the market.
ViCapsys Life Sciences (OTC PINK:VICP) announced on September 29, 2022, the appointment of Mr. Richard Rosenblum, Dr. Colleen Delaney, and Mr. Charles Farrahar to its Board of Directors, effective September 22, 2022. This move comes as Dr. John Potts and Mr. Michael Yurkowsky step down from their positions. The new board members bring over 75 years of combined financial and pharmaceutical experience, which the company views as crucial for advancing its strategic plan, particularly focusing on CXCL12 technology aimed at treating Type I diabetes.
ViCapsys Life Sciences has appointed Federico Pier as the permanent CEO, effective February 15, 2022. Pier, who has been the interim CEO since August 2020, is credited with establishing a solid foundation for the company’s mission in developing therapeutic solutions, particularly in the field of diabetes. With over 25 years of experience in finance and life sciences, his leadership is expected to guide the company through its expansion into additional therapeutics. ViCapsys focuses on proprietary products for transplantation therapies and post-surgical needs.
FAQ
What is the current stock price of Vicapsys Life Sc (VICP)?
What is the market cap of Vicapsys Life Sc (VICP)?
